X0306 4 2019-07-01 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001779990 HENDERSON MICHAEL THOMAS C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 See Remarks Common Stock 2019-07-01 4 M 0 8420 A 8420 D Common Stock 2019-07-01 4 M 0 8420 A 16840 D Common Stock 2019-07-01 4 M 0 151563 A 168403 D Common Stock 2019-07-01 4 M 0 5364 A 173767 D Common Stock 2019-07-01 4 P 0 7000 17.00 A 180767 D Management Incentive Units 2019-07-01 4 M 0 8420 0.00 D Common Stock 8420 0 D Management Incentive Units 2019-07-01 4 M 0 8420 0.00 D Common Stock 8420 0 D Management Incentive Units 2019-07-01 4 M 0 151563 0.00 D Common Stock 151563 0 D Management Incentive Units 2019-07-01 4 M 0 5364 0.00 D Common Stock 5364 0 D Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 22, 2016, such that the shares shall be fully vested on March 22, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of January 1, 2017, such that the shares shall be fully vested on January 1, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 31, 2018, such that the shares shall be fully vested on October 31, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. Senior Vice President, Asset Acquisition, Strategy and Operations Ralph Scarborough, as Attorney-in-fact 2019-07-03